New antibiotic battle aims to protect vulnerable gut patients
NCT ID NCT06794944
Summary
This study aims to find out which of two common antibiotics, fidaxomicin or vancomycin, is better at clearing C. difficile bacteria from the gut of people with inflammatory bowel disease (IBD). About 60 adult patients will be randomly assigned to take one of the antibiotics for 10 days, and neither they nor the doctors will know which one they receive. Researchers will check stool samples over several months to see if the bacteria is gone and if clearing it helps improve IBD symptoms and prevents future infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.